-
Reduce the mortality of specific hospitalized patients by 20%, the phase 3 clinical results
Time of Update: 2021-09-07
On June 16, 2021, Regeneron announced that its research neutralizing antibody therapy REGEN-COV (casirivimab and imdevimab) has obtained positive preliminary results in the Phase 3 clinical trial RECOVERY .
-
Specific pancreatic cancer remission rate is 42%. Initial clinical results of innovative bispecific antibody therapy are positive
Time of Update: 2021-06-22
In the treatment of pancreatic cancer patients with NRG1 fusion-positive, zenocutuzumab achieved a confirmed total remission rate of 42% (5/12) .
Zenocutuzumab is a bispecific antibody that targets both HER2 and HER3 receptors, designed to accurately treat patients with solid tumors that are positive for NRG1 fusion .
-
ASCO specific pancreatic cancer patients have a response rate of 42%, and initial clinical results of innovative bispecific antibody therapy are positive
Time of Update: 2021-06-17
In the treatment of pancreatic cancer patients with NRG1 fusion-positive, zenocutuzumab achieved a confirmed total remission rate of 42% (5/12) .
Zenocutuzumab is a bispecific antibody that targets both HER2 and HER3 receptors, designed to accurately treat patients with solid tumors that are positive for NRG1 fusion .
-
ASCO doubles the OS of specific TNBC patients with Trop-2 antibody conjugated drug Phase 3 results are positive
Time of Update: 2021-06-10
The latest results in a phase 3 clinical trial in patients with triple negative breast cancer (TNBC).
It has been approved for Phase 3 clinical trials in China to treat metastatic triple-negative breast cancer and advanced urothelial cancer that have received at least 2 lines of previous treatment.
-
Jansen EGFR/MET dual-specific antibodies had positive results in the treatment of specific non-small cell lung cancer
Time of Update: 2021-03-12
Janssen, a unit of Johnson and Johnson, has released the latest results for its dual-specific antibody amivantamab, which is used to treat patients with metastasis or inexorable small cell lung cancer (NSCLC) inserted in the treatment of exosome 20 that carries a dermis growth factor (EGFR).
-
Roche long-acting dual-specific antibody Phase 3 clinical results actively treat specific macular degeneration patients
Time of Update: 2021-01-30
half (45%) of patients in the two studies received faricimab treatment every 16 weeks in the first year, the first time an eye injection drug treated with namAMD has reached such a long duration in Phase 3 clinical trials.
-
Dual-specific antibody TR009 / ABL001 targeting VEGF / DLL4 treats gastroesic tumors with encouraging preclinical results
Time of Update: 2021-01-14
in the Notch path, Delta-like liage 4 (DLL4) plays an important role in affecting tumor angiogenesic angiogenesy, which inhibits the formation of new blood vessels and promotes the maturation of new blood vessels.
-
ASH |。 Jansen first published the clinical results of "first-in-class" dual-specific antibody therapy;
Time of Update: 2020-12-18
Recently, at the annual meeting of the American Society of Hematology (ASH), Janssen announced the latest developments in several projects in its research and development pipeline for the treatment of blood cancer, including the "first-in-class" dual special of the target GPRC5D target for innovative multiple myeloma (MM) Heterosexual antibody talquetamab, as well as the twin-specific therapy teclistamab targeting B-cell mature antigens (BCMA) and the CAR-T therapy Citacabtagene Autoleucel (cilta-cel), developed in collaboration with Legendary Biology.
-
CAR-T treatment failure patients can also completely mitigate the results of dual-specific antibody clinical trials positive
Time of Update: 2020-06-02
B-NHL includes types such as diffuse large B-cell lymphoma (DLBCL) and ostosis (FL) DLBCL is a rapidly developing B-NHL, with up to 50% of advanced patients developing disease after first-line therapy
-
Clinical results of double specific antibody precision therapy for the treatment of specific pancreatic cancer/lung cancer patients
Time of Update: 2020-06-01
NRG1 gene fusion variation refers to the gene that expresses NRG1 and other genes, resulting in an increase in NRG1 expression levels The frequency of NRG1 gene fusion is not high, and it occurs in ab
-
Positive clinical results of bispecific antibody precision therapy for specific pancreatic cancer / lung cancer patients
Time of Update: 2019-10-29
Today, merus announced the preliminary clinical results of its bispecific antibody mcla-128 (also known as zenocutuzumab) in the treatment of cancer patients carrying NRG1 gene fusion Mcla-128 is a bi